While the broader market spent June fixated on the SpaceX IPO, the Federal Reserve transition, and a chip-driven selloff, something quieter and arguably more consequential has been building in small cap biotech. Over the past several weeks, the sector has produced a steady stream of value-moving catalysts — reverse mergers, patent wins, acquisitions at steep premiums, and AI partnerships — that collectively point to one of the most active catalyst environments the space has seen in years. For investors who understand how small cap biotech actually creates value, that activity is worth paying close attention to.